Bristol Myers Squibb

Pharmaceuticals
BMY
$ 50 0.3
Share price
$ 102 bn
Market Cap
$ 134 bn
Enterprise Value

Carbon footprint

2.8 Ton
GHG emissions per $ 1 mln investment
0.08x the weighted average for S&P 500
FY2021
How is this calculated?
+33%
YOY change in GHG emissions
Stronger than the +0.5% weighted average for S&P 500
FY2021 vs. previous year

Primary Climate Goal

-5.3%
Proj. YOY change in GHG emissions (Scope 1 + 2)
Weaker than the -8.2% weighted average for S&P 500
FY2022
How is this calculated?

Bristol Myers Squibb aims to achieve carbon neutrality for Scope 1 + 2 by 2040


This target has not been verified as science based according to SBTi
Bristol Myers Squibb's actual and proj. GHG emissions (Scope 1 + 2) (Kt of CO2e)

GHG emissions and Carbon intensity

Bristol Myers Squibb's GHG emissions (market-based) (Kt of CO2e)
Bristol Myers Squibb's Carbon intensity (Tons per 1 USDm)

Bristol Myers Squibb's carbon footprint

Bristol Myers Squibb reported Total CO2e Emissions - Market-Based Scope 1 + Scope 2 for the twelve months ending 31 December 2021 at 371 Kt (+92/+33% y-o-y). Carbon intensity also increased to 8 t (+1.5/+23% y-o-y).

Bristol Myers Squibb's Scope 3 emissions surged to 1,890 Kt (+1,878/+15792% y-o-y). The parameter has been fairly volatile.

The company is committed to achieving carbon neutrality for Scope 1 + 2 by 2040, which translates into the estimated reduction of -20 Kt per annum over the period of FY2022 - FY2040. This target, however, has not been recognised as science-based (and as aligned with Paris Agreement) by the SBTi.

Bristol Myers Squibb aims to achive carbon neutrality across its operations (Scope 1 + 2) in 2040. Companies normally become carbon neutral with the help of the acquisition of carbon offsets rather than absolute reductions in their own greenhouse emissions. Also, carbon neutrality does not include non-CO2 GHG emissions.

Company environmental metrics

Show more...